Therapeutic Asset Ratings

9,922 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Nivolumab Systemic Sclerosis	National Cancer Institute (NCI)	P1	CC (43)
Nivolumab Virus Associated Tumor	National Cancer Institute (NCI)	P1	CC (43)
NKG2D CAR-NK Metastatic Malignant Neoplasm	Zhejiang University	P1	CC (43)
nkg2d-car-nk92 cells Refractory Malignant Neoplasm	Henan Medical University	P1	CC (43)
nkg2d car t-cells Metastatic Malignant Neoplasm	Zhejiang University	P1	CC (43)
nkt3447 Gastric Carcinoma	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3447 Endometrial Disorder	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3447 Breast Carcinoma	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3447 Her2-Receptor Negative Breast Cancer	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3447 Metastatic Neoplasm	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3447 Progesterone-Receptor Positive Breast Cancer	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Gastric Carcinoma	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Endometrial Disorder	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Breast Carcinoma	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Her2-Receptor Negative Breast Cancer	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Endometrial Carcinoma	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Metastatic Neoplasm	NiKang Therapeutics, Inc.	P1	CC (43)
nkt3964 Progesterone-Receptor Positive Breast Cancer	NiKang Therapeutics, Inc.	P1	CC (43)
nkt5097 cdk2/cdk4 dual degrader Hormone Receptor-Positive Breast Cancer	NiKang Therapeutics, Inc.	P1	CC (43)
nkx019 Aggressive B-Cell Non-Hodgkin Lymphoma	Nkarta, Inc.	P1	CC (43)
nkx019 Anaplastic Large Cell Lymphoma	Nkarta, Inc.	P1	CC (43)
nkx101 - car nk cell therapy Acute Myeloid Leukemia	Nkarta, Inc.	P1	CC (43)
nm32-2668 Lung Adenocarcinoma	Numab Therapeutics AG	P1	CC (43)
nm32-2668 Gastric Adenocarcinoma	Numab Therapeutics AG	P1	CC (43)
nm32-2668 Liposarcoma	Numab Therapeutics AG	P1	CC (43)

Showing 2951 to 2975 of 9,922 assets

PreviousPage 119 of 397Next